Drug Profile
Research programme: phosphodiesterase 7A and 4 dual inhibitors - Astellas
Alternative Names: YM-393059Latest Information Update: 02 Mar 2011
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class
- Mechanism of Action Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Inflammation; Rheumatoid arthritis
Most Recent Events
- 02 Feb 2007 Preclinical trials in Asthma in Japan (unspecified route)
- 02 Feb 2007 Preclinical trials in Inflammation in Japan (unspecified route)
- 02 Feb 2007 Preclinical trials in Rheumatoid arthritis in Japan (unspecified route)